| Today’s Big NewsJan 11, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now. 
|
|
| By Max Bayer Takeda cemented itself as a player in the immunology arena when it bought Nimbus' TYK2 inhibitor a year ago, putting it toe-to-toe against Bristol Myers Squibb. Now, the Japanese pharma has detailed just how the drug landed in its pipeline. |
|
|
|
By Nick Paul Taylor BioNTech is continuing to add to its sprawling R&D portfolio without denting its cash mountain. Chinese service provider WuXi Biologics is the latest company to feed the biotech’s appetite for assets, accepting a $20 million offer for monoclonal antibodies against two undisclosed targets. |
By Max Bayer Sanofi CEO Paul Hudson did not rule out further business development related to Pompe disease despite the FTC's challenge of its deal with Maze Therapeutics. The pharma company's concern is that the latest action could result in the death of the program due to a lack of funding. |
By Angus Liu Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates, Pfizer’s newly minted chief oncology officer Chris Boshoff, Ph.D., said in an interview. But the company isn’t considering large buyouts at the moment. |
By Annalee Armstrong,Gabrielle Masson,James Waldron,Max Bayer,Ben Adams We're off for another day of the J.P. Morgan Healthcare Conference 2024. The flood of licensing deals and M&A may have slowed, but there's still plenty of action to come as companies make pitches to their peers, investors and industry watchers. |
By Joseph Keenan Fortrea, the CRO that spun out of Labcorp last year, is linking up with trial software provider Veeva Systems and regulatory review company Advarra to leverage their services to streamline clinical trials. |
By Zoey Becker With expertise gained from years of experience, Catalent is a "top-positioned CDMO" in the booming GLP-1 field, its chief executive said. Its planned expansions prime the company to reap the benefits of the market's rapid growth in the years to come. |
By Andrea Park After inking a deal worth up to $75 million to acquire joint pain devicemaker Vyrsa Technologies late last year, Nevro now appears to be trying to lessen the impact of those costs on its bottom line. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
